Prostate cancer can often be found early by testing the amount of prostate-specific antigen (PSA), discussed in detail below, in your blood. Prostate cancer may also be found on a digital rectal exam (DRE), in which your doctor inserts a gloved finger into the rectum.
Prostate cancer is the most common male cancer diagnosed in Western populations.
Autopsy studies have shown that with increasing age, the majority of
men will develop microscopic foci of cancer (often termed “latent” prostate
cancer) and that this is true in populations that are at both high and low risk for
the invasive form of the disease (1). However, only a small percentage of men
will develop invasive prostate cancer. The prevalence of prostate cancer is,
thus, very common; but to most men, prostate cancer will be only incidental to
their health and death....
Prostate cancer is one of the most common types of cancer in men and its treatment was constricted to surgery for confined state and androgen ablation for advanced disease until new options have become available. The present book covers a broad range of novel aspects of prostate cancer diagnosis, treatment and patient care, as well as new research on relevant cell biology.
The European Association of Urology (EAU) Guidelines Group for Prostate Cancer have prepared this
guidelines document to assist medical professionals assess the evidence-based management of prostate
cancer. The multidisciplinary panel of experts include urologists, radiation oncologists, a medical oncologist,
and a pathologist.
Where possible a level of evidence (LE) and/or grade of recommendation (GR) have been assigned
(1). Recommendations are graded in order to provide transparency between the underlying evidence and the
recommendation given (Tables 1 and 2)...
“Advances in Prostate Cancer” is an addition to the InTech collection of three previous
books about prostate cancer and aims at providing a comprehensive overview of specific
aspects of the latest research and current knowledge relating to this tumor entity to
scientists and clinicians. For this purpose a series of research articles, clinical investigations
and reviews that deal with a wide range of relevant aspects pertinent to the epidemiology,
diagnosis, patient care, treatment and basic biology of prostate cancer were included.
For decades we have been learning about the interplay between tumors and the
immune system. Our knowledge seemed somewhat incomplete and indirect, like
listening to the ocean waves through a shell. Only recently, cancer immunotherapy has
started to become a reality, with Provenge (Dendreon Corporation, WA), an
autologous antigen-presenting cell preparation, earning the approval of United States
Food and Drug Administration (FDA) for the treatment of advanced prostate cancer in
It has been said that the control of disease has three goals, which, in
increasing order of attraction are palliation, cure, and prevention. For most types
of disseminated cancer, medical science has achieved only the first of these
objectives, while for some malignancies the side effects of the therapeutic agents
employed rival the disease itself in precluding a desirable quality of life.
Prostate cancer treatment dates back almost
100 years. However, in an era of rapid developments
and innovations in cancer research and
uro-oncology, there is an increasing need to
update our knowledge and especially to guide
our practice by innovations and evidence-based
medicine. Prostate cancer is still evolving following
improvements in disease detection and
better understanding of disease characteristics.
Immune system is composed of innate and adaptive responses and plays critical
roles in cancer development and destruction. A century ago, Paul Ehrlich postulated
that cancer would be quite common in long-lived organisms if not for the protective
effects of immunity. About 50 years later, Burnet and Thomas proposed the concept
of cancer immunosurveillance based on the experimental evidence of immune recognition
of tumor antigens expressed on tumor cells (Dunn et al. 2004 ) . In 1971, the
US Congress created a National Cancer Act – a War on Cancer.
Diagnosis and Treatment by Clinical State
The disease continuum—from the appearance of a preneoplastic and invasive lesion localized to the prostate, to a metastatic lesion that results in symptoms and, ultimately, mortality from prostate cancer—can span decades. Management at all points is centered on competing risks that are defined by considering the disease as a series of clinical states (Fig. 91-1).
Tuyển tập các báo cáo nghiên cứu khoa học ngành y học tạp chí Medical Sciences dành cho các bạn sinh viên ngành y tham khảo đề tài: A 12 Week, Open Label, Phase I/IIa Study Using Apatone® for the Treatment of Prostate Cancer Patients Who Have Failed Standard Therapy...
Tuyển tập các báo cáo nghiên cứu về sinh học được đăng trên tạp chí hóa học quốc tế đề tài : Urinary and sexual outcomes in long-term (5+ years) prostate cancer disease free survivors after radical prostatectomy
Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành hóa học dành cho các bạn yêu hóa học tham khảo đề tài: A novel multiplex assay combining autoantibodies plus PSA has potential implications for classification of prostate cancer from non-malignant cases
Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành hóa học dành cho các bạn yêu hóa học tham khảo đề tài: A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899
Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành hóa học dành cho các bạn yêu hóa học tham khảo đề tài: F-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with 223Ra-chloride (Alpharadin)
Estrogen receptors (ERs) and androgen receptors, members of the steroid hormone family of nuclear receptors, are targets of inhibition by drugs used to treat breast and prostate cancers, respectively. Tamoxifen, a partial agonist and antagonist of ER function, can mediate tumor regression in metastatic breast cancer and can prevent disease recurrence in the adjuvant setting, saving thousands of lives each year. Tamoxifen binds to the ER and modulates its transcriptional activity, inhibiting activity in the breast but promoting activity in bone and uterine epithelium.
The noninvasive proliferation of epithelial cells within ducts is termed prostatic intraepithelial neoplasia. PIN is a precursor of cancer, but not all PIN lesions develop into invasive cancers. Of the cancers identified, 95% are adenocarcinomas; the remainder are squamous or transitional cell tumors or, rarely, carcinosarcomas. Metastases to the prostate are rare, but in some cases colon cancers or transitional cell tumors of the bladder invade the gland by direct extension.
Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Radiation Oncology cung cấp cho các bạn kiến thức về ngành y đề tài: "Analysis of health related quality of life (HRQoL) of patients with clinically localized prostate cancer, one year after treatment with external beam radiotherapy (EBRT) alone versus EBRT and high dose rate brachytherapy (HDRBT)...
Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài:
Hypertrophic osteoarthropathy as the cause of a super scan of the bone in a patient with prostate cancer: a case report